Evidence map›Paper›PMID 31988999›Full record

ArticleRegenerative therapy2020

A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells.

Yasutaka Fujita, Masuhiro Nishimura, Natsuki Watanabe Komori, Tamaki Wada, Chikage Shirakawa, Taichi Takenawa, Osamu Sawamoto, Masako Doi

Open access · goldAbstract read
In one paragraph

Article in Regenerative therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yasutaka FujitaResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Masuhiro NishimuraResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Natsuki Watanabe KomoriResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Tamaki WadaResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Chikage ShirakawaResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Taichi TakenawaResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Osamu SawamotoResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Masako DoiResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Otsuka (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy.

methodsWe determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line.

resultsOptimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. DISCUSSION: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics

Indexed as

Cell preservation solutionDextran 40hADSCs, human adipose-derived mesenchymal stromal cellsHuman adipose-derived mesenchymal stromal cellsLR-3T-5D, lactated Ringer's solution with 3% trehalose and 5% dextran 40LR-3T, lactated Ringer's solution with 3% trehaloseMSCs, mesenchymal stromal cellsTrehalose

Identifiers

PMID31988999
PMCPMC6970134
OpenAlexW2999347695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.